Abbott Sublicenses Lateral Flow Technology to Calypte

A sublicense for certain worldwide rights to patents relating to the design, manufacture, and sale of lateral-flow rapid diagnostic tests has been granted by Abbott Laboratories (Abbott Park, IL, USA) to Calypte Biomedical Corp. (Pleasanton, CA, USA).

Under the terms of the agreement, Calypte was granted certain worldwide rights to use a family of patents known as the Guire/Swanson patents. The technology underlying these patents is fundamental to all lateral-flow rapid diagnostic tests. At the recent International AIDS Conference in Bangkok (Thailand), there was a focus on efforts to quickly identify people with HIV more quickly. Calypte plans to offer a menu of tests providing the HIV testing community with the option to choose from a complete line of rapid tests that can be used to test urine, oral fluid, and blood.

"We are pleased to have received a license to the Guire/Swanson patents from Abbott,” said Dr. Richard George, CEO of Calypte. "The technology covered by these patents is critical to the design of lateral-flow rapid tests. We believe it is one of the essential licenses that will provide us the freedom to manufacture and sell our emerging HIV rapid diagnostic tests in the U.S. and around the world.”




Related Links:
Abbott
Calypte